Ocrevus Zunovo now approved in US to treat relapsing MS, PPMS
WEB6 days ago · The U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab), for treating...
Genentech: Press Releases | Friday, Sep 13, 2024
WEBSep 13, 2024 · Ocrevus Zunovo™ offers people with multiple sclerosis (MS) more options to access treatment based on their individual needs. South San Francisco, CA -- September 13, 2024 --. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus ...
AAN 2024: Subcutaneous Ocrevus shows benefits after 1 year
WEBApr 23, 2024 · A subcutaneous (under-the-skin) formulation of Ocrevus (ocrelizumab) helped most adults with multiple sclerosis (MS) remain free of clinical relapses and new or worsening brain lesions, according...
New Data for Genentech’s Ocrevus Show That After 10 Years of …
WEBOct 12, 2023 · Ocrevus is the first and only disease-modifying treatment (DMT) in MS to benefit both people with RMS and PPMS and now has 10 years of follow-up data from its three Phase III trials.
ECTRIMS 2023: New under-the-skin Ocrevus found effective in MS
WEBOct 12, 2023 · by Marisa Wexler, MS October 12, 2023. A new under-the-skin formulation of Ocrevus (ocrelizumab) — administered in 10 minutes — is at least as effective as the approved intravenous, or...
Positive Results Announced from Phase 3 OCARINA II Trial …
WEBJul 13, 2023 · OCARINA II is a global Phase III multicentre, randomised study evaluating the pharmacokinetics, safety and radiological and clinical effects of the subcutaneous formulation of OCREVUS compared ...
Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) …
WEBJul 13, 2023 · Ocrevus is a humanized monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and...
FDA approves new drug to treat multiple sclerosis | FDA
WEBOn March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple...
FDA Approves Ocrevus Zunovo™ | National MS Society
WEBSep 13, 2024 · The U.S. Food and Drug Administration recently approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq, Genentech) as a twice-a-year healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC, under the skin) injectable disease-modifying therapy. This medication is approved for people living with both relapsing ...
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a …
WEBSep 16, 2024 · OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's office ... View the performance of global markets and browse news items by region. Equities screener. Find companies based on country, sector, and other equity characteristics.
Skip to content